PsychedelicNewsBreaks – Pure Extracts Corp. Leverages CO2 Technology in ‘Extraction Is Our Business’ Model

Pure Extracts, a private, plant-based extraction company with a new vertical in functional mushrooms, leverages CO2 technology, a process based on pressurized carbon dioxide that provides some of today’s cleanest, healthiest products. The company’s dedication to this process was highlighted in a recent article, which reads, “Pure Extract’s Vitalis C02 extraction technology allows for full-spectrum oil extraction, which results in the purest, highest-quality oil. In addition, the company, which notes that ‘extraction is our business,’ will soon have the capacity for more than 100,000 kg of biomass per year with a technique that has been tried and tested through its teams’ industry experience (http://ibn.fm/ohQl6).”

To view the full article visit http://ibn.fm/Wgndu

About Pure Extracts

Pure Extracts is positioned to enter the commercial cannabis sector, as well as a new vertical in functional mushrooms, as an experienced producer. Led by a team of qualified experts and providing cutting-edge CO2 extraction technology, the company is set up for long-term strategic distribution and product innovation. For more information, visit the company’s website at www.PureExtractsCorp.com.

NOTE TO INVESTORS: The latest news and updates relating to Pure Extracts are available in the company’s newsroom at http://ibn.fm/Pure

About PsychedelicNewsBreaks

PsychedelicNewsBreaks (NNB) provide a rapid summary of corporate news that caught the attention of PsychedelicNewsWire (PNW). NNB keeps you up-to-date on active US Public Companies complementary to PNW’s broader scope as a provider of news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of contributing journalists and writers, PNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. PNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, PNW brings its clients unparalleled visibility, recognition and brand awareness. PNW is where news, content and information converge.

Please see full disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.psychedelicnewswire.com/disclaimer/

PsychedelicNewsWire (PNW)
San Francisco, CO
www.psychedelicnewswire.com
415.949.5050 Office
Editor@PsychedelicWire.com

Chris@PNW

Share
Published by
Chris@PNW

Recent Posts

PsychedelicNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) to Join H.C. Wainwright’s 27th Annual Global Investment Conference; CEO Fireside Chat Set for Sept. 8, 2025, 4:30 to 5 p.m. ET

NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, and HOPE Therapeutics, Inc. (“HOPE”), an interventional…

4 days ago

PsychedelicNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Showcases HOPE Therapeutics at Global Passion Project Event 

NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, presented two keynote talks at the Global…

5 days ago

PsychedelicNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Announces Expanded Access Policy for NRX-100 Following FDA Fast Track Designation

NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, announced its expanded access policy for NRX-100…

2 weeks ago

PsychedelicNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Reports Q2 2025 Results, Highlights Progress Across Lead Programs and Strategic Investment

NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, reported financial results for the quarter ended…

3 weeks ago

PsychedelicNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Receives FDA Fast Track Designation for NRX-100 in Treating Suicidal Ideation in Depression 

NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, announced the U.S. Food and Drug Administration…

4 weeks ago

PsychedelicNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Subsidiary HOPE Therapeutics(TM) Secures Florida Regulatory Clearance to Close Dura Medical Acquisition

NRx Pharmaceuticals (NASDAQ: NRXP), through its wholly owned subsidiary HOPE Therapeutics(TM), Inc., announced it has…

4 weeks ago